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Abstract Age-related lobular involution (LI) is a physi-
ological process in which the terminal duct lobular units of
the breast regress as a woman ages. Analyses of breast
biopsies from women with benign breast disease (BBD)
have found that extent of LI is negatively associated with
subsequent breast cancer development. Here we assess the
natural course of LI within individual women, and the
impact of progressive LI on breast cancer risk. The Mayo
Clinic BBD cohort consists of 13,455 women with BBD
from 1967 to 2001. The BBD cohort includes 1115 women
who had multiple benign biopsies, 106 of whom had
developed breast cancer. Within this multiple biopsy
cohort, the progression of the LI process was examined by
age at initial biopsy and time between biopsies. The rela-
tionship between LI progression and breast cancer risk was
assessed using standardized incidence ratios and by Cox
proportional hazards analysis. Women who had multiple
biopsies were younger age and had a slightly higher family
history of breast cancer as compared with the overall BBD
cohort. Extent of LI at subsequent biopsy was greater with
increasing time between biopsies and for women age
55 ? at initial biopsy. Among women with multiple
biopsies, there was a significant association of higher breast
cancer risk among those with involution stasis (lack of
progression, HR 1.63) as compared with those with invo-
lution progression, p = 0.036. The multiple biopsy BBD
cohort allows for a longitudinal study of the natural pro-
gression of LI. The majority of women in the multiple
biopsy cohort showed progression of LI status between
benign biopsies, and extent of progression was highest for
women who were in the perimenopausal age range at initial
biopsy. Progression of LI status between initial and sub-
sequent biopsy was associated with decreased breast cancer
risk.
Keywords Lobular involution  Benign breast disease 
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Introduction
Age-related lobular involution (LI) is a physiological pro-
cess in which the epithelial tissue of the breast gradually
regresses, corresponding with elimination of the need for
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milk production beyond the child-bearing years. Analysis
of the Mayo Clinic cohort of more than 13,000 women who
had a breast biopsy with benign findings and were thus
diagnosed with benign breast disease (BBD) showed that
the timing of LI centers around the perimenopausal years
but varies considerably among women [1–3], with com-
plete LI in 8.5 % of women\40 years of age [1, 3], while
more than half of women over 50 with BBD have not
completed the process of LI [1, 4, 5]. Investigation of LI in
a sample of breast tissues from normal donors demon-
strated reductions in acini counts per terminal duct lobular
unit (TDLU) starting in the 3rd decade of life and slowing
of this process in the 6th decade [6].
The Mayo BBD Cohort includes 13,455 women, ages
18–85 at biopsy, who had a breast biopsy with benign
findings at Mayo Clinic 1967–2001, and of whom 1273
have subsequently developed breast cancer [7]. In the
Mayo BBD Cohort, LI extent at initial biopsy was cate-
gorized qualitatively as none (0 % lobules involuted),
partial (1–74 % involuted) or complete (C75 % involuted),
and progressive degrees of LI were found to be associated
with a significantly reduced risk of breast cancer [1]. These
results were subsequently confirmed in an analysis of
patient samples from the Nurses’ Health Study, which
found that smaller lobular size was associated with
decreased cancer risk [8]. While an association between
progressive LI and reduced breast cancer risk is consistent
with the understanding that breast lobules are the anatomic
substructure that gives rise to breast cancer [9], these
findings were particularly robust in that progressive
degrees of LI were associated with reduced cancer risk
even in subsets of women at high-risk due to epithelial
proliferation. Thus, even for women with atypical hyper-
plasia (atypia), a high-risk subset (overall relative risk
[RR] = 4 for cancer development), patients with no LI in
the background lobules had substantially higher risk of
subsequent breast cancer than those who had completed
involution (RR = 7.79 vs. 1.49, respectively), and for
postmenopausal women in particular, evidence of no or
partial LI was associated with a 3-fold increased breast
cancer risk as compared to women in which the LI process
had been completed.
Previous studies of LI status have involved evaluations
of cohorts at single time points, and identification of the
relationship between progressive stages of LI and breast
cancer risk was limited by an inability to distinguish
between women who had undergone LI at some point in
the past and women who may never have developed
extensive lobular structures. We have now identified from
the Mayo BBD cohort a group of 1115 women who had
multiple, sequential benign biopsies, with time between
biopsies from 60 days to more than 15 years. Within this
multiple biopsy cohort, we have assessed for the first time
the relationship between age and LI progression over time
within individual women, and have evaluated how active




The Mayo BBD Cohort has been described previously [10,
11] and currently comprises 13,455 women ages 18–85
who underwent benign breast biopsies between 1967 and
2001 at Mayo Clinic (Rochester, MN). Demographic
clinical features and risk factors were identified from
medical records and questionnaires [10, 11]. Evaluation of
patient records identified 1115 women who had undergone
at least one additional benign biopsy more than 60 days
after the initial biopsy (multiple biopsy cohort).
Demographic and clinical characteristics were collected
using study questionnaires and comprehensive medical
record review. Family history of breast cancer was cate-
gorized as strong, weak, or negative. A strong family his-
tory was defined as the patient having (1) at least one first-
degree relative with breast cancer diagnosed before age
50 years or (2) two relatives with breast cancer at any age,
with at least one being a first-degree relative. Blood rela-
tives from either the mother’s or father’s side were inclu-
ded. Members adopted into the family, or members from
any potential spouse were not included. Patients with
family history of breast cancer who did not meet the above
criteria were categorized as having a weak family history.
Breast cancer events were ascertained from study
questionnaires, tumor registry, and review of medical
records. With a median of 21.9 years of follow-up for the
multiple biopsy cohort, 106 women have been diagnosed
with breast cancer. The study protocol, including patient
contact and follow-up methods, was approved by the Mayo
Clinic Institutional Review Board with methods previously
described [1].
Histologic examination
The study breast pathologist (DWV) performed histologic
review of archived H&E slides from the subsequent benign
biopsies, and histologic features were recorded. Biopsy
findings were classified by the most extreme degree of
hyperplasia as nonproliferative, proliferative disease with-
out atypia, or atypical hyperplasia, as previously reported
[7]. LI status was previously assessed in the initial biopsy
for the entire cohort according to a three-level catego-
rization: non-involuted, 0 %; partial involution, 1–75 %;
complete involution, 75–100 % [1]. The LI status of the
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initial and subsequent biopsies for the patients in the
multiple biopsy cohort were assessed using a four-level
metric to provide increased resolution of LI status: 0–25 %
involuted, 26–50 %, 51–74 %, and 75–100 %.
Statistical methods
Data were summarized using means and standard devia-
tions for continuous variables and percentages and fre-
quencies for categorical variables. Occurrence of
subsequent biopsy was compared across levels of cate-
gorical variables (age of BBD, breast cancer status, overall
impression, involution, family history of breast cancer,
number of children) using Pearson Chi-squared tests for
significance. Kruskal–Wallis tests were used for continu-
ous covariates (duration of follow-up). Age-adjusted
comparisons were also performed using logistic regression.
To determine if women with multiple benign biopsies
were representative of the overall BBD cohort, associations
were examined between previously published risk factors
and later breast cancer [12]. Results from subsetting to
women with multiple benign biopsies were compared to
results from the overall BBD cohort. The duration of fol-
low-up was calculated as the number of days from first
biopsy of the benign lesion to the date of the diagnosis of
breast cancer, death, prophylactic mastectomy, reduction
mammoplasty, LCIS, or last contact. Internal comparisons
were performed using hazard ratio (HR) estimates using a
conventional Cox proportional hazards regression analysis.
External comparisons were performed using relative risk
(RR) estimates from standardized incidence ratios (SIRS).
SIRS are an external comparison of the number of
observed breast cancers versus the number expected using
age-year specific incidence rates of breast cancer from the
Iowa Surveillance, Epidemiology, and End Results (SEER)
registry, and were calculated using methods in previous
publications [13].
Associations between LI progression at second biopsy
and features at index biopsy were assessed using logistic
regression. Time between biopsies, age at index biopsy,
and involution at index were included as predictors.
Women with LI[75 % at index were not included in this
comparison due to their inability to progress. Each variable
was initially examined univariately in separate logistic
regression models. After this, we fit one overall multi-
variate logistic model that included all variables to assess
the independent effects on LI progression.
Comparisons of breast cancer risk at second biopsy were
performed using multiple methods. Internal comparisons
were made using Cox proportional hazards regression.
Duration of follow-up was calculated in the same fashion
as above with date of second biopsy as the starting time
point. Time was modeled as a function of age using start
and stop methods rather than time on study [14]. Like in
the logistic analyses, women with LI[75 % at index were
not included in either comparison due to their inability to
progress. Covariates examined included LI at index biopsy,
overall impression at index biopsy, and change in involu-
tion from index to second biopsy. Each variable was
examined univariately in separate Cox models. An overall
multivariate Cox model including all variables was used to
assess independent effects on risk of breast cancer. Exter-
nal comparisons of breast cancer risk at second biopsy
were performed using SIRS. LI at second biopsy, change in
involution, and histologic impression at second biopsy
were examined. All statistical tests were 2 sided and con-
ducted using SAS statistical software (SAS institute Inc.,
Cary, NC). A p value\0.05 was determined significant.
Results
LI progression and breast cancer risk in multiple
biopsy cohort
Of the 13,455 patients in the Mayo BBD cohort, 1115 were
found to have had multiple, sequential benign biopsies
(Supplemental Table 1). Comparison of baseline patient
characteristics between the multiple biopsy BBD cohort
and the rest of the BBD cohort revealed that the multiple
biopsy cohort is significantly younger (p\ 0.001) and was
followed longer (median 20.7 years follow-up for multiple
biopsy cohort as compared to 15.4 years for the rest of the
BBD cohort, p\ 0.001). Women in the multiple biopsy
cohort were significantly more likely to show proliferative
disease without atypia at the initial biopsy (PDWA;
p = 0.014 univariate, p\ 0.001 when adjusted for patient
age at initial biopsy) and had a stronger family history of
breast cancer (p\ 0.001) than the remainder of the cohort.
LI status was assessed for the initial and subsequent
biopsies using a four-level metric to provide increased
resolution of LI status: 0–25 % involuted, 26–50, 51–74,
and 75–100 % (Fig. 1). Comparison of the LI status for the
multiple biopsy group showed significantly lower levels of
involution as compared to the rest of the BBD cohort, even
when adjusted for patient age (p\ 0.001). Of the women
in the multiple biopsy cohort, 106 subsequently developed
breast cancer (cases), while 1009 remained cancer-free
(controls); this relative proportion of cases vs. controls
showed no significant difference as compared to the rest of
the BBD cohort (age-adjusted p = 0.876).
Breast cancer risk (observed versus expected) was
assessed through standardized incidence ratios (SIRs) for
the overall BBD cohort and the multiple biopsy BBD
cohort (Supplemental Table 2). In the entire BBD cohort,
categories of LI status at initial biopsy, overall histologic
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impression, and age at initial biopsy were all significantly
associated with later breast cancer risk. By contrast, LI
status and age initial biopsy and were not significantly
associated with later breast cancer risk in the multiple
biopsy cohort, possibly due in part to the younger age of
the multiple biopsy cohort as well as the increased follow-
up time for women in this cohort, since women in this
group did not have breast cancer between biopsies, which
shifts their risk profile.
Hazard ratios (HRs) for breast cancer risk in the
overall cohort and in the multiple biopsy cohort were
calculated via Cox regression, which allows for adjust-
ment of other covariates including time from first biopsy
to second biopsy and histologic impression (Supplemen-
tal Table 3). These results showed a strong and progres-
sive reduction of risk by LI status for the overall BBD
cohort, while no significant HR differences were seen for
categorical LI in the multiple biopsy BBD cohort when
Fig. 1 Qualitative assessment
of age-related lobular
involution. All images are at the
same magnification. Scale bar
500 lm
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assessed at initial biopsy, possibly due in part to the
smaller sample size.
Rate of LI progression by patient age in the multiple
biopsy cohort
Women were assigned to the category LI progression when
the subsequent biopsy was assessed as having a greater
extent of LI as compared to the initial biopsy (0–25 % at
initial biopsy to 26–100, 25–50 % to 51–100, or 51–74 %
at initial biopsy to 75–100 %; N = 507); women showing
complete involution at initial biopsy (N = 281) were
excluded from consideration for LI progression. Patients
were assigned to the category LI stasis when the subse-
quent biopsy was assessed as having the same or decreased
degree of LI status (75–100 to 0–100 %, 26–74 to 0–74 %,
and 0–25 to 0–25 %; N = 327; Table 1).
The relative proportion of patients showing LI pro-
gression increased with longer time between biopsies,
although this effect was most significant for women who
had initial biopsies at ages\45 and 45–55, as women who
had initial biopsy greater than age 55 were largely com-
pletely involuted at their initial biopsy (Supplemental
Table 4). Calculation of adjusted odds ratios for LI pro-
gression (Table 2) revealed a significantly higher incidence
of LI progression when time between biopsies was greater
than 2 years, with generally increasing LI progression rates
at longer time points (as compared with patients having
time between biopsies\2 years, adjusted for age at BBD
and LI status at initial biopsy). Evaluation by age at initial
biopsy showed greatest incidence of LI progression from
non-involuted or partially involuted states for patients
[55 years (as compared with patients with initial biopsy at
ages\45 years, adjusted for time between biopsy and LI
status at initial biopsy), and reducing likelihood of LI
progression with greater extent of LI at initial biopsy (ad-
justed for time between biopsy and age at initial biopsy).
Use of hormone replacement therapy (HRT) was available
for 85 % of the patients in the multiple biopsy cohort, but
no information was available for whether HRT was used
prior to first biopsy, between biopsies, or after the subse-
quent biopsy. HRT usage was not found to be significantly
associated with involution progression (p = 0.482,
Table 2).
Effect of LI progression or stasis on breast cancer
risk
HRs were also calculated to examine the effect of LI
progression vs. LI stasis (Table 1) on breast cancer risk
following the subsequent biopsy (Table 3). For these
analyses, follow-up was defined as time from second
biopsy to breast cancer event or censorship. These results
showed that LI stasis patients had a significant increase in
breast cancer risk as compared with LI progression patients
after accounting for LI at the index biopsy and all other
variables listed in the table (HR 1.63 [95 % CI 1.03–2.57],
p = 0.036). We also performed a similar analysis in which
follow-up time was stratified on time since first biopsy
(\10 years vs. 10 ? years), and found similar results, with
a slightly weaker (though still significant) association with
involution progression (HR 1.64 [95 % CI 1.02–2.64),
p = 0.041; Supplemental Table 5).
We also evaluated SIRs, which allow for comparison
with an outside group, in the multiple biopsy group based
on time from subsequent biopsy to later breast cancer
(Table 4). These analyses revealed a higher overall SIR for
the multiple biopsy BBD patients (1.93 [95 % CI
1.53–2.39], as compared to 1.65 [95 % CI 1.56–1.74] for
the overall BBD cohort and 1.35 [95 % CI 1.11–1.64] for
the multiple biopsy BBD cohort at initial biopsy, Supple-
mental Table 2). SIRs for LI status at subsequent biopsy
were also larger for no LI (2.94 [95 % CI 1.61–4.93], as
compared to 2.08 [95 % CI 1.83–2.36] for patients with no
LI in the overall BBD cohort and 1.41 [95 % CI 0.93–2.06]
for patients from the multiple biopsy BBD cohort with no
LI at initial biopsy, Supplemental Table 2). Strikingly,
SIRs at subsequent biopsy for patients with LI stasis were
Table 1 LI status at initial biopsy vs. subsequent biopsy in the multiple biopsy cohort
LI status at subsequent biopsy
0–25 % TDLU
(N = 92) (%)
26–50 % TDLU
(N = 238) (%)
51–75 % TDLU
(N = 317) (%)
[75 % TDLU
(N = 468) (%)
LI status at initial biopsy
0–25 % TDLU 77 (83.7) 84 (35.3) 75 (23.7) 64 (13.7)
26–50 % TDLU 9 (9.8) 95 (39.9) 100 (31.5) 82 (17.5)
51–75 % TDLU 3 (3.3) 41 (17.2) 102 (32.2) 102 (21.8)
[75 % TDLU 3 (3.3) 18 (7.6) 40 (12.6) 220 (47.0)
Women categorized as LI progression (N = 507) are colored blue, women categorized as LI stasis (N-327) are colored red, and women with
complete involution ([75 %) at initial biopsy were excluded from consideration as LI progression versus stasis
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increased as compared with patients with LI progression
(Table 4; LI progression, 1.59 [95 % CI 1.13–2.17] versus
LI stasis, 2.44 [95 % CI 1.76–3.28], p = 0.054). Thus, at
time of subsequent biopsy, when the association between
LI status and breast cancer risk is much closer to that of the
overall BBD cohort, ongoing LI is associated with a mar-
ginally significant decrease in breast cancer risk as com-
pared to stalled LI.
Discussion
In this study, we define a cohort of 1115 women from
within the larger Mayo BBD cohort who had multiple,
sequential benign biopsies at the Mayo Clinic. We find that
there are differences between the women in the multiple
biopsy cohort as compared with the overall BBD cohort, in
that they are significantly younger and more likely to have
Table 2 Associations with involution progression using multivariate logistic regression
Characteristic LI progression
(N = 507) (%)
LI stasis
(N = 327) (%)
Multivariate
Odds ratio (95 % CI) Wald p value
Time from Index to later benign biopsy \.001
\2 44 (8.7) 82 (25.1) 1.00 (ref)
2–5 98 (19.3) 97 (29.7) 2.10 (1.21, 3.65)
5–10 130 (25.6) 86 (26.3) 3.58 (2.08, 6.14)
10? 235 (46.4) 62 (19.0) 9.18 (5.30, 15.89)
Age at index bx \.001
\45 273 (53.8) 189 (57.8) 1.00 (ref)
45–55 192 (37.9) 105 (32.1) 2.24 (1.50, 3.35)
55? 42 (8.3) 33 (10.1) 1.89 (1.00, 3.58)
Involution at index \.001
0–25 % TDLU 223 (44.0) 77 (23.5) 1.00 (ref)
26–50 % TDLU 182 (35.9) 104 (31.8) 0.50 (0.33, 0.76)
51–75 % TDLU 102 (20.1) 146 (44.6) 0.16 (0.10, 0.26)
HRT ever/never 0.482
No 172 (39.1) 113 (41.5) 1.00 (ref)
Yes 268 (60.9) 159 (58.5) 0.88 (0.62, 1.26)
AH atypical hyperplasia, BBD benign breast disease, NP nonproliferative disease, PDWA proliferative disease without atypia, TDLU terminal
duct lobular units. All shown covariates were modeled simultaneously in a single multivariate model
a p value is from an overall type 3 wald test
Table 3 Breast cancer hazard ratios for multiple biopsy cohort including effect of LI progression
Characteristic Total (N = 834) Events (N = 82) (%) Multivariate
Hazard ratio (95 % CI) Wald p valuea
Involution at index 0.527
0–25 % TDLU 300 27 (9.0) 1.00 (ref)
26–50 % TDLU 286 29 (10.1) 0.87 (0.51, 1.48)
51–75 % TDLU 248 26 (10.5) 0.72 (0.40, 1.28)
Change in involution 0.036
Progression 507 39 (7.7) 1.00 (ref)
Stasis 327 43 (13.1) 1.63 (1.03, 2.57)
Overall impression \.001
NP 475 31 (6.5) 1.00 (ref)
PDWA 317 42 (13.2) 2.10 (1.31, 3.35)
AH 42 9 (21.4) 5.49 (2.56, 11.81)
Four-level involution assessments were used to determine LI progression vs. LI stasis. Follow-up time was assessed from time at second biopsy
AH atypical hyperplasia, BBD benign breast disease, NP nonproliferative disease, PDWA proliferative disease without atypia, TDLU terminal
duct lobular units. All shown covariates were modeled simultaneously in a single multivariate model
a p value is from an overall type 3 wald test
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a family history of breast cancer, although the age-adjusted
incidence of breast cancer in the multiple biopsy cohort
was essentially the same. Evaluation of change of LI status
between initial and subsequent biopsy provided the
expected finding that progressive LI was more common
with increasing time between biopsies (Supplemental
Table 4) and in peri- and post-menopausal women
(Table 2). Previous studies of LI and breast cancer risk
have consistently found that increased LI status is associ-
ated with decreased breast cancer risk [8, 15–20], but these
studies only examined women at single points in time. This
is the first study to examine individual women at multiple
time points. We also found that LI status was strongly
associated with breast cancer risk when assessed at sub-
sequent biopsy (Table 4), though this relationship was
weaker when assessed at initial biopsy (Supplemental
Table 2). This difference is likely a consequence of the
increased follow-up time for women in the multiple biopsy
cohort, since by definition, women in this group did not
have breast cancer between biopsies, which necessarily
shifted their risk profile.
Nearly three-quarters of breast cancer cases are diag-
nosed at age 50 or higher [21], and considerable research
effort has been directed to understanding how the process
of aging is linked to breast cancer development. Of note,
the greatest increase in rate of breast cancer occurs during
the peri- and early postmenopausal years [22], where we
also find greatest evidence for ongoing progression of the
LI process (Table 2). Our previous investigations with the
BBD cohort have revealed that breast cancer risk is con-
centrated in the 40 % of postmenopausal women for whom
the process of LI is delayed [1], and our findings presented
here reveal that women in the multiple biopsy BBD group
who do not have LI progression between initial and sub-
sequent biopsies are at significantly increased risk as
compared with women who do show LI progression
(Table 4). Further investigations as to the information
present at a histological or molecular level in the benign
breast biopsies of the women in the multiple biopsy BBD
cohort could reveal mediators driving the process of LI. By
extension, these mediators could further provide insight
into why LI is delayed in many postmenopausal women
and why these women are at increased risk for develop-
ment of breast cancer.
This is the first investigation of LI changes across time
in individual women, and the first demonstration that
stalled LI is a significant predictor of increased breast
cancer risk. Strengths of the study include centralized
pathological review for all BBD patients and for the initial
and subsequent biopsies in the multiple biopsy cohort, as
well as the large size of the multiple biopsy cohort and the
ability to compare with the entire BBD cohort. Weaknesses
include the significant differences in average age between
the multiple biopsy cohort as compared with the overall
Table 4 Standard incidence ratios of breast cancer development for multiple biopsy cohort from time of subsequent biopsy






SIR (95 % CI)a p valueb
Overall 834 11,865 82 42.15 1.95 (1.55, 2.41)
Involution at 2nd Bx 0.096
0–25 % TDLU 89 1622 14 4.76 2.94 (1.61, 4.93)
26–50 % TDLU 220 3299 22 10.25 2.15 (1.34, 3.25)
51–75 % TDLU 277 3998 31 14.81 2.09 (1.42, 2.97)
[75 % TDLU 248 2946 15 12.33 1.22 (0.68, 2.01)
Change in involution 0.054
Progression 507 6557 39 24.51 1.59 (1.13, 2.17)
No progression 327 5308 43 17.64 2.44 (1.76, 3.28)
Impression at 2nd Bx 0.034
NP 387 5856 27 19.32 1.40 (0.92, 2.03)
PDWA 352 5034 42 18.92 2.22 (1.60, 3.00)
AH 91 915 12 3.66 3.28 (1.69, 5.72)
Comparison of number of observed breast cancers versus number expected using age-year specific incidence rates of breast cancer from the Iowa
SEER registry
AH atypical hyperplasia, BBD benign breast disease, NP nonproliferative disease, PDWA proliferative disease without atypia, SIR standardized
incidence ratio, TDLU terminal duct lobular units
a The SIR compares the observed number of breast cancer events with the number expected on the basis of Iowa Surveillance, Epidemiology,
and End-results data. All analyses account for the effects of age and calendar period
b p values test heterogeneity across levels of the covariate
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BBD cohort, as well as the limited power of our statistical
comparisons. In conclusion, this study revealed that pro-
gressive LI status has a protective mechanism for breast
cancer development, and might be utilized as a risk marker
in breast cancer risk assessment models. Further longitu-
dinal studies involving BBD cohorts are encouraged to
evaluate the progression of LI and breast cancer
development.
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